New treatment for herpes simplex virus type 2 [ultrasound and zinc, urea and tannic acid ointment]. Part II: Female patients.
Clinical treatment of 147 female patients suffering with genital herpes simplex virus were conducted in two phases. The purpose of Phase I was to note the efficacy of treatment with ultrasound and Herpigon ointment (zinc, urea, and tannic acid) in relieving pain and shortening the length of time involved in healing. Results indicated that the combined treatment significantly reduced pain and length of healing period. Phase II involved a 2-year follow-up of patients with primary and recurrent infection. Results indicated that the combined treatment significantly reduced recurrent infection in all patients treated.
D000328:Adult; D005260:Female; D006561:Herpes Simplex / Q000628:therapy*; D006801:Humans; D047348:Hydrolyzable Tannins / Q000627:therapeutic use*; D009824:Ointments; D012008:Recurrence; D013634:Tannins / Q000627:therapeutic use*; D014464:Ultrasonic Therapy; D014508:Urea / Q000627:therapeutic use*; D002575:Uterine Cervicitis / Q000188:drug therapy; D014848:Vulvovaginitis / Q000188:drug therapy*; D015032:Zinc / Q000627:therapeutic use*
D047348:Hydrolyzable Tannins; D009824:Ointments; D013634:Tannins; D014508:Urea; D015032:Zinc